keyword
MENU ▼
Read by QxMD icon Read
search

Sinusoidal obstruction syndrome

keyword
https://www.readbyqxmd.com/read/29903766/cytoprotective-and-pro-angiogenic-functions-of-thrombomodulin-are-preserved-in-the-c-loop-of-the-fifth-epidermal-growth-factor-like-domain
#1
Xiangmin Wang, Bin Pan, Goichi Honda, Xintao Wang, Yuko Hashimoto, Hiroshi Ohkawara, Kailin Xu, Lingyu Zeng, Takayuki Ikezoe
We previously found that the fifth epidermal growth factor-like domain of thrombomodulin (TME5) exerts cytoprotective and pro-angiogenic functions via G-protein coupled receptor 15 (GPR15). TME5 is comprised of three S-S bonds that divide it into three loops: A (TME5A), B (TME5B), and C (TME5C). Here, we identified the minimum structure of TME5 that produces favorable effects in vascular endothelial cells (ECs). We found that TME5C, composed of 19 amino acids, but not TME5A or TME5B, stimulated the proliferation of human umbilical vein endothelial cells (HUVECs) and human hepatic sinusoidal endothelial cells (HHSECs)...
June 14, 2018: Haematologica
https://www.readbyqxmd.com/read/29895929/hepatic-veno-occlusive-disease-following-sirolimus-based-immune-suppression
#2
Farhad Khimani, George B McDonald, Howard M Shulman, Brian Betts, Frederick Locke, Hugo Fernandez, Claudio Anasetti, Joseph Pidala
Sirolimus-based graft vs. host disease (GVHD) prophylaxis is associated with higher incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allogeneic hematopoietic cell transplantation (HCT). However, whether the clinical manifestations and prognosis of VOD/SOS differs when diagnosed in the setting of sirolimus-based GVHD prophylaxis is not well studied. To address this question, we examined presenting features and treatment outcome of VOD/SOS cases identified in a large retrospective cohort of consecutive HCT procedures (n = 818 total, sirolimus (SIR)/tacrolimus (TAC) n = 308, and methotrexate (MTX) or mycophenolate mofetil (MMF)/TAC n = 510)...
June 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29873895/defibrotide-for-the-treatment-of-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome-following-nontransplant-associated-chemotherapy-final-results-from-a-post-hoc-analysis-of-data-from-an-expanded-access-program
#3
Nancy A Kernan, Paul G Richardson, Angela R Smith, Brandon M Triplett, Joseph H Antin, Leslie Lehmann, Yoav Messinger, Wei Liang, Robin Hume, William Tappe, Robert J Soiffer, Stephan A Grupp
BACKGROUND: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially fatal complication of conditioning for hematopoietic stem cell transplantation (HSCT) but can occur after nontransplant-associated chemotherapy. Following HSCT, VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States...
June 6, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29844459/the-effect-of-n-acetyl-l-cysteine-nac-on-liver-toxicity-and-clinical-outcome-after-hematopoietic-stem-cell-transplantation
#4
Ibrahim El-Serafi, Mats Remberger, Ahmed El-Serafi, Fadwa Benkessou, Wenyi Zheng, Eva Martell, Per Ljungman, Jonas Mattsson, Moustapha Hassan
Busulphan (Bu) is a myeloablative drug used for conditioning prior to hematopoietic stem cell transplantation. Bu is predominantly metabolized through glutathione conjugation, a reaction that consumes the hepatic glutathione. N-acetyl-l-cysteine (NAC) is a glutathione precursor used in the treatment of acetaminophen hepatotoxicity. NAC does not interfere with the busulphan myeloablative effect. We investigated the effect of NAC concomitant treatment during busulphan conditioning on the liver enzymes as well as the clinical outcome...
May 29, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29844205/comparison-of-pediatric-allogeneic-transplant-outcomes-using-myeloablative-busulfan-with-cyclophosphamide-or-fludarabine
#5
Andrew C Harris, Jaap J Boelens, Kwang Woo Ahn, Mingwei Fei, Allistair Abraham, Andrew Artz, Christopher Dvorak, Haydar Frangoul, Cesar Freytes, Robert Peter Gale, Sanghee Hong, Hillard M Lazarus, Alison Loren, Shin Mineishi, Taiga Nishihori, Tracey O'Brien, Kirsten Williams, Marcelo C Pasquini, John E Levine
Busulfan combined with cyclophosphamide (BuCy) has long been considered a standard myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (HCT), including both nonmalignant conditions and myeloid diseases. Substituting fludarabine for cyclophosphamide (BuFlu) to reduce toxicity without an increase in relapse has been increasingly performed in children, but without comparison with BuCy. We retrospectively analyzed 1781 children transplanted from 2008 to 2014 to compare the effectiveness of BuCy with BuFlu...
June 12, 2018: Blood Advances
https://www.readbyqxmd.com/read/29803752/a-novel-ultrasonographic-scoring-system-of-sinusoidal-obstruction-syndrome-after-hematopoietic-stem-cell-transplantation
#6
Mutsumi Nishida, Kaoru Kahata, Eiko Hayase, Akio Shigematsu, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Takahito Iwai, Junichi Sugita, Hitoshi Shibuya, Chikara Shimizu, Takanori Teshima
BACKGROUND: Sinusoidal obstruction syndrome (SOS)/hepatic veno-occlusive disease (VOD) is a well-documented complication after hematopoietic stem cell transplantation (HSCT). Transabdominal ultrasonography (US) enables to visualize blood flow abnormalities and is therefore useful for the diagnosis of SOS/VOD. We herein prospectively evaluated accuracy of a novel ultrasonographic diagnostic scoring system of SOS/VOD based on US findings. METHODS: We carried out US in 106 patients on day 14 and when SOS/VOD was suspected after allogeneic HSCT...
May 24, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29792719/-sinusoidal-obstruction-syndrome-induced-by-monocrotaline-in-a-large-animal-experiment-a-pilot-study
#7
R Pálek, V Liška, V Třeška, J Rosendorf, M Emingr, V Tégl, A Králíčková, K Bajcurová, M Jiřík, Z Tonar
INTRODUCTION: Sinusoidal obstruction syndrome (SOS) is a disease which is caused by toxic injury to hepatic sinusoids. This syndrome is most frequently caused by myeloablative radiochemotherapy in patients before hematopoietic stem cells transplantation and also by oxaliplatin mainly in patients with colorectal liver metastases. The aim of this study was to establish a large animal model of SOS, which would enable further study of this disease and facilitate translation of experimental outcomes into human medicine...
2018: Rozhledy V Chirurgii: Měsíčník Československé Chirurgické Společnosti
https://www.readbyqxmd.com/read/29790787/colorectal-liver-metastases-a-pathologist-s-guide-to-creating-an-informative-report-and-improving-patient-care
#8
Mariana Moreno Prats, Eizaburo Sasatomi, Heather L Stevenson
CONTEXT: - In this era of minimally invasive procedures for diagnosis, prognosis, and treatment, pathologists are at the forefront of analyzing specimens and are expected to make more specific diagnoses, providing additional information from the material they receive. OBJECTIVE: - To familiarize pathologists with the essential components of surgical pathology reports for colorectal liver metastases (CRLM) resections. DATA SOURCES: - Colorectal cancer is the third most common cancer in the world and the liver is the most frequent site of metastases...
May 23, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29787942/thrombotic-and-hemorrhagic-complications-in-children-and-young-adult-recipients-of-hematopoietic-stem-cell-transplant-hsct
#9
Dominder Kaur, Aneel A Ashrani, Rajiv Pruthi, Shakila P Khan, Kent Bailey, Vilmarie Rodriguez
BACKGROUND: Overall incidence of hemostatic complications in pediatric recipients of Hematopoietic Stem Cell Transplant (HSCT) is scarcely studied. This retrospective review explored the incidence and underlying risk factors of bleeding and thrombotic complications in children. PROCEDURE: Clinical characteristics, hemorrhagic events (HE), thrombotic events (TE) and follow up data were abstracted from medical records on patients aged <21 years undergoing HSCT during January 2000-June 2015...
April 26, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29774103/bevacizumab-exacerbates-sinusoidal-obstruction-syndrome-sos-in-the-animal-model-and-increases-mmp-9-production
#10
Azin Jafari, Hanno Matthaei, Sven Wehner, Tolga Tonguc, Jörg C Kalff, Steffen Manekeller
Background: Thanks to modern multimodal treatment the ouctome of patients with colorectal cancer has experienced significant improvements. As a downside, agent specific side effects have been observed such as sinusoidal obstruction syndrome (SOS) after oxaliplatin chemotherapy (OX). Bevazicumab targeting VEGF is nowadays comprehensively used in combination protocols with OX but its impact on hepatotoxicity is thus far elusive and focus of the present study. Results: After MCT administration 67% of animals developed SOS...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29767845/final-results-from-a-defibrotide-treatment-ind-study-for-patients-with-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome
#11
Nancy A Kernan, Stephan Grupp, Angela R Smith, Sally Arai, Brandon Triplett, Joseph H Antin, Leslie Lehmann, Tsiporah Shore, Vincent T Ho, Nancy Bunin, Massimo Iacobelli, Wei Liang, Robin Hume, William Tappe, Robert Soiffer, Paul Richardson
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic stem cell transplant (HSCT) conditioning and chemotherapy. Defibrotide is approved for treatment of hepatic VOD/SOS with pulmonary or renal dysfunction [i.e., multi-organ dysfunction (MOD)] after HSCT in the United States and severe VOD/SOS after HSCT in patients aged older than 1 month in the European Union. Defibrotide was available as an investigational drug by an expanded-access treatment programme (T-IND; NCT00628498)...
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29715079/sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-stem-cell-transplant-insights-and-therapeutic-advances
#12
REVIEW
Samah Nassereddine, Saud Alsubait, Imad Tabbara
Hepatic sinusoidal obstruction syndrome (SOS) is a rare fatal clinical entity seen following hematopoietic stem cell transplant (HSCT). It is more commonly reported to occur following allogeneic HSCT compared to autologous HSCT. Historically, it is known as hepatitis following HSCT. It is thought that endothelial damage to the hepatic venules leading to occlusion of the terminal hepatic venules and hepatic sinusoids is the trigger for the development of SOS. Several risk factors have been associated with this condition...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29703039/hepatic-veno-occlusive-disease-related-to-gynura-segetum-a-case-report
#13
Ziyi Sun, Jianmei Kang, Yongchang Zhang
INTRODUCTION: Hepatic veno-occlusive disease (HVOD), as known as hepatic sinusoidal obstruction syndrome (HSOS), is an obliterative venulitis of the terminal hepatic venules, which is responsible for considerable mortality. The potential mechanism is destruction of hepatic sinusoidal endothelial cells (SEC), with sloughing and downstream occlusion of terminal hepatic venules. Here, we report a case of HVOD who have a history of ingestion of Gynura segetum for 1 month. The patient presents for abdominal pain and distension...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29673920/-sinusoidal-obstruction-syndrome-after-beam-conditioning-regiment-for-autologous-stem-cell-transplantation-imputability-of-bendamustine-report-of-two-cases-and-literature-review
#14
A Meyer, L-M Fornecker, A Guffroy, A-S Korganow, M Martin
INTRODUCTION: Sinusoidal obstruction syndrome is a rare complication of autologous hematopoietic stem cell transplantation. This syndrome is mainly described following conditioning regiment with busulfan, cyclophosphamide and/or total body irradiation. CASE REPORTS: We report for the first time two cases of sinusoidal obstruction syndrome occurring lately after BeAM conditioning regiment (bendamustine, etoposide, aracytine, melphalan) for autologous stem cell transplantation in patients treated for malignant lymphoma...
April 16, 2018: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29572158/a-phase-i-ii-trial-of-the-combination-of-azacitidine-and-gemtuzumab-ozogamicin-for-treatment-of-relapsed-acute-myeloid-leukemia
#15
Bruno C Medeiros, Tiffany N Tanaka, Larisa Balaian, Asad Bashey, Amy Guzdar, Hongying Li, Karen Messer, Edward D Ball
INTRODUCTION: Treatment with hypomethylating agent therapy might enhance anti-CD33 monoclonal antibody-mediated cytotoxicity against acute myeloid leukemia (AML) blasts through epigenetic effects on Syk and SHP-1 expression. PATIENTS AND METHODS: In the present phase I/II study, we treated patients with relapsed or refractory AML with azacitidine, followed by 2 doses of gemtuzumab ozogamicin (GO) at 6 mg/m2 , the Food and Drug Administration-approved dose and schedule at study initiation...
May 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29537138/-pre-emptive-strike-the-case-for-early-treatment-of-hepatic-sinusoidal-obstruction-syndrome-with-defibrotide
#16
Revathi Rajagopal, Marianne B Phillips, Nicholas G Gottardo
The initial signs of hepatic sinusoidal obstruction syndrome (HSOS) can be challenging to recognize in children, especially outside the hematopoietic stem cell transplantation setting. To assist clinicians to promptly identify HSOS, the European Society for Blood and Marrow Transplantation has proposed pediatric HSOS diagnostic criteria which emphasize unexplained consumptive and transfusion-refractory thrombocytopenia. To highlight the importance of these "bellwether" early signs of HSOS and the efficacy of pre-emptive treatment with defibrotide, we describe the case of a child with a right 11th rib primitive neuroectodermal tumor who developed HSOS following focal radiotherapy and actinomycin-D treatment...
March 14, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29519713/sinusoidal-obstruction-syndrome-veno-occlusive-disease-complication-in-lymphoma-patients-treated-with-oxaliplatin-based-regimen-a-case-series-report
#17
E Bernichon, E Daguenet, C Molla, J Cornillon, C Lejeune, F Casteillo, D Guyotat, E Tavernier
AIM: SOS/VOD is a relevant clinical syndrome that usually appears early after hematopoietic stem cell transplantation. The purpose of this article was to report a case series of SOS/VOD in non-susceptible patients and draw physicians' attention to the plausible relationship between liver injury and oxaliplatin-based chemotherapy, preceding autologous transplantation. METHODS: In this study, we report a case series of SOS/VOD in 4 lymphoma patients following autologous transplantation...
March 5, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29477779/defibrotide-for-sinusoidal-obstruction-syndrome-veno-occlusive-disease-prophylaxis-in-high-risk-adult-patients-a-single-center-experience-study
#18
Adrien Picod, Agnès Bonnin, Giorgia Battipaglia, Federica Giannotti, Annalisa Ruggeri, Eolia Brissot, Florent Malard, Clémence Médiavilla, Ramdane Belhocine, Anne Vekhoff, Mor Sény Gueye, Simona Lapusan, Rosa Adaeva, Françoise Isnard, Ollivier Legrand, Minh-Tam Baylatry, Anne-Christine Joly, Myriam Labopin, Rémy Duléry, Mohamad Mohty
Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is a serious complication after hematopoietic stem cell transplantation (HSCT). SOS/VOD usually occurs within 3 weeks of HSCT, but the 2016 European Society for Blood and Marrow Transplantation diagnosis criteria have been revised to include late forms. Prophylactic use of defibrotide is recommended in the pediatric setting, but its value remains uncertain in the adult population. We report here a single-center series of 63 adult patients considered at high risk for SOS/VOD who received defibrotide prophylaxis in combination with ursodeoxycholic acid between May 2012 and August 2016...
March 1, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29468059/oxaliplatin-induced-hepatic-sinusoidal-obstruction-syndrome-in-a-patient-with-gastric-cancer-a-case-report
#19
Fang Liu, Xin Cao, Jin Ye, Xiaoli Pan, Xuefeng Kan, Yuhu Song
Oxaliplatin is a platinum-based antineoplastic agent used in cancer chemotherapy. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome (HSOS) has been reported in the context of chemotherapy for liver metastasis of colorectal cancer. However, to the best of our knowledge, there is no report of oxaliplatin-associated HSOS in patients with gastric cancer. The present study reported a patient with gastric cancer who received proximal gastrectomy and oxaliplatin-containing chemotherapy. Contrast-enhanced computed tomography revealed that liver parenchyma appeared heterogeneous and demonstrated hypoattenuation in the portal phase...
March 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29458270/the-involvement-of-nrf2-antioxidant-signaling-pathway-in-the-protection-of-monocrotaline-induced-hepatic-sinusoidal-obstruction-syndrome-in-rats-by-catechin-hydrate
#20
Xiaoqi Jing, Jiaqi Zhang, Zhenlin Huang, Yuchen Sheng, Lili Ji
Hepatic sinusoidal obstruction syndrome (HSOS) is a rare and life-threatening liver disease. (+)-catechin is a natural dietary flavonol with high antioxidant capacity. This study aims to investigate the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant signaling pathway in the protection of (+)-catechin hydrate (CAT) against monocrotaline (MCT)-induced HSOS. Results of serum alanine/aspartate aminotransferases (ALT/AST) activities, total bilirubin (TBil) and bile acids (TBA) amounts, liver histological observation, scanning electron microscope evaluation and hepatic metalloproteinase-9 (MMP-9) expression all demonstrated the protection of CAT against MCT-induced HSOS in rats...
February 20, 2018: Free Radical Research
keyword
keyword
18880
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"